title: [Effectiveness of new, once-daily 5-aminosalicylic acid in the treatment of ulcerative colitis].
abstract: 5-aminosalicylate (5-ASA) agents remain the mainstay treatment in ulcerative colitis (UC). A number of oral 5-ASA agents is commercially available, including azo-bond pro-drugs such as sulfasalazine, olsalazine and balsalazide, and delayed- and controlled-release forms of mesalazine. In addition, the effectiveness of oral therapy relies on good compliance, which may be adversely affected by frequent daily dosing and a large number of tablets. Furthermore, poor adherence has been shown to be an important barrier to successful management of patients with UC. Recently, new, once-daily formulations of mesalazine including the unique multi-matrix delivery system and mesalazine granules were proven to be efficacious in inducing and maintaining remission in mild-to-moderate UC, with a good safety profile comparable to that of other oral mesalazine formulations. In addition, they offer the advantage of low pill burden and may contribute to increased long-term compliance and treatment success in clinical practice and might potentially further contribute to a decline in the risk for UC-associated colon cancers. In this systematic review, the authors summarize the available literature on the short- and medium-term efficacy and safety of the new once-daily mesalazine formulations.
authors.affiliation: Semmelweis Egyetem, Altalános Orvostudományi Kar I. Belgyógyászati Klinika Budapest Korányi S. 2/A 1083. kislakpet@bell.sote.hu
authors.forename: Péter László
authors.initials: PL
authors.lastname: Lakatos
authors.forename: László
authors.initials: L
authors.lastname: Lakatos
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D004334:Drug Administration Schedule; D006801:Humans; D055118:Medication Adherence; D019804:Mesalamine / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D012074:Remission Induction; D012720:Severity of Illness Index
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine